Redeye updates its estimates and valuation following Momentum Group’s Q3 2025 report. Net sales came in slightly below our estimates, with the 7% y/y increase driven by M&A. Still, EBITA was better than expected due to a well-contained OPEX base. With relatively modest leverage and strong capital efficiency, the company retains ample M&A firepower. We expect continued acquisition activity and make only minor estimate revisions following the report. Our updated fair value range supports a neutral stance on the share at present, although it could remain an attractive opportunity for investors with a long-term view and confidence in continued solid execution.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/